Chinese developers of RNA-based therapies, including small interfering RNA medicines, have extended their venture capital and private equity fundraising streak into early December.
Suzhou Sanegene Bio brought in one of the biggest rounds of financing in the RNA area so far in 2023. The Chinese RNA interference specialist on 1 December announced an...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?